Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

NCT: NCT05403723 · SUSPENDED

NCT IDNCT05403723
StatusSUSPENDED
Start Date2027-01-30
Completion2028-08
SponsorUniversity of Maryland, Baltimore (OTHER)
First posted
Last updated

Brief Summary

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

Frequently Asked Questions

What is Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC?

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC is a clinical trial registered under NCT05403723. Current status: SUSPENDED.

What is the status of NCT05403723?

The current status of NCT05403723 (Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC) is: SUSPENDED.

When did Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC start?

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC started on 2027-01-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑